期刊文献+

雄激素非依赖性前列腺癌的治疗进展 被引量:7

Current Opinions on the Treatment of Androgen-independent Prostate Cancer
下载PDF
导出
摘要 前列腺癌是男性泌尿生殖系常见的恶性肿瘤之一,在我国发病率虽较低,但近年来随着人口老龄化及生活条件的改善,发病率有明显增加的趋势。几乎所有一开始对内分泌治疗敏感的前列腺癌最终都将发展成雄激素非依赖性前列腺癌(AIPC)。AIPC是指对内分泌治疗无反应或内分泌治疗后反而促进疾病进展,导致不可逆的临床进展恶化,直至患者死亡。有关AIPC的发病机制以及治疗策略仍缺乏统一的认识,现就此作一综述。 Prostate cancer is a most common malignant neoplasm in males. In recent years, its incidence has been rising dramatically in China. Patients with recurrent prostate cancer may be treated with androgen deprivation strategies, but most cases will eventually develop into androgen-independent prostate cancer (AIPC). Until recently, chemotherapy has been shown to be effecdtive in palliating the symptoms of the disease but not in improving survival. Current strategies for the treatment of AIPC have shown significant palliation, but no definitive increase in survival. Molecular mechanisms underlying the development of androgen-independent prostate cancer (AIPC) are poorly understood. However, there is growing evidence that different molecular profiles may result in the development of AIPC. In this paper, we not only review the molecular mechanism of AIPC, but also present some of the promising management principles and systemic chemotherapy options against AIPC.
出处 《中华男科学杂志》 CAS CSCD 2006年第11期1021-1025,共5页 National Journal of Andrology
基金 国家自然科学基金项目(30470669)
关键词 前列腺癌 雄激素非依赖性 治疗 prostate cancer androgen-independent treatment
  • 相关文献

参考文献21

  • 1Bubley GJ,Carducci M,Dahut W,et al.Eligibility and response guidelines for phase Ⅱ clinical trials in androgen-independent prostate cancer:recommendations from the Prostate-Specific Antigen Working Group[J].J Clin Oncol,1999,17 (11):3461-3467.
  • 2Hernes E,Fossa SD,Berner A,et al.Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence[J].Br J Cancer,2004,90(2):449-454.
  • 3Edwards J,Krishna NS,Mukherjee R,et al.The role of c-Jun and c-Fos expression in androgen-independent prostate cancer[J].J Pathol,2004,204(2):153-158.
  • 4Doganavsargil B,Simsir A,Boyacioglu H,et al.A comparison of p21 and p27 immunoexpression in benign glands,prostatic intraepithelial neoplasia and prostate adenocarcinoma[J].BJU Int,2006,97(3):644-648.
  • 5Lynch RL,Konicek BW,McNulty AM,et al.The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation[J].Mol Cancer Res,2005,3 (3):163-169.
  • 6Bland L B,Garzotto M,DeLoughery T G,et al.Phase Ⅱ study of transdermal estradiol in androgen-independent prostate carcinoma[J].Cancer,2005,103(4):717-723.
  • 7Dowling A J,Panzarella T,Ernst D S,et al.A retrospective analysis of the relationship between changes in serum PSA,palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer[J].Ann Oncol,2001,12(6):773-778.
  • 8Glode LM,Barqawi A,Crighton F,et al.Metronomic therapy with cyclophosphamide and dexamethas one for prostate carcinoma[J].Cancer,2003,98(8):1643-1648.
  • 9Berry W,Dakhil S,Modiano M,et al.Phasse Ⅲ study of mitoxantrone plus low dose prednisone versus low doseprednisone alone in patients with asymptomatic hormone refractory prostate cancer[J]J Urol,2002,168(6):2439-2443.
  • 10Joshua AM,Nordman I,Venkataswaran R,et al.Weekly docetaxel as second line treatment after mitozantrone for androgenindependent prostate cancer[J].Intern Med J,2005,35 (8):468 -472.

同被引文献62

引证文献7

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部